13F reference period
Q2 2026
Security Snapshot
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) Institutional Ownership
CUSIP: 320703408
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
22
Shares (Excl. Options)
525.55K
Full value: 525,545 · shares · 30 Jun 2026Price
$0.17
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- CLDI on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 525,545
- Total 13F value
- $89,344
- Portfolio coverage rank
- 0%
- Share change
- -1,482,334
- Value change
- -$365,494
- Number of holders
- 22
- Shares outstanding
- 7,142,857
- SEC-reported price per share
- $1.07
- Insider filing price
- $1.07
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 320703408.
- 22 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 27 to 22 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$478.79K
Full value: $478,788 · USD · 31 Mar 2026.$89.34K
Full value: $89,344 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 22 institutions filings for Q2 2026.
Security key
320703408
13F reference period
Q2 2026
13F holders
22
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
CLDI full holder history
Calidi Biotherapeutics, Inc. SEC filings
Calidi Biotherapeutics, Inc. company facts
Calidi Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 320703408:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
CLDI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | 117,368 | Armistice Capital, LLC | 30 Jun 2025 | ||||
| Gavrilov Ognian Anguelov | 0.3% | -95% | $6,600 | -$224,400 | 20,000 | -97% | Gavrilov Ognian Anguelov | 31 Mar 2026 |
As of 30 Jun 2026,
22
institutional investors reported holding
shares of
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI).
This represents
7.4%
of the company’s total
outstanding shares.
525.55K
Full value: 525,545 · shares · 30 Jun 20267.14M
Full value: 7,142,857 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 625 | $669 | -$19,525 | $1.07 | 1 |
| 2026 Q2 | 525,545 | $89,344 | -$365,494 | $0.17 | 22 |
| 2026 Q1 | 2,007,879 | $478,788 | +$226,762 | $0.24 | 27 |
| 2025 Q4 | 448,323 | $524,682 | +$271,225 | $1.17 | 27 |
| 2025 Q3 | 211,031 | $320,773 | +$320,773 | $1.52 | 21 |